MCID: FML005
MIFTS: 45

Female Reproductive Endometrioid Cancer

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Female Reproductive Endometrioid Cancer

MalaCards integrated aliases for Female Reproductive Endometrioid Cancer:

Name: Female Reproductive Endometrioid Cancer 12 15 17
Endometrioid Tumor 12 70
Female Reproductive Endometrioid Neoplasm 12
Endometrioid Neoplasm 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3001
NCIt 50 C7113
SNOMED-CT 67 253013001
UMLS 70 C0474809

Summaries for Female Reproductive Endometrioid Cancer

Disease Ontology : 12 A female reproductive organ cancer that is characterized by a resemblance to endometrium.

MalaCards based summary : Female Reproductive Endometrioid Cancer, also known as endometrioid tumor, is related to fallopian tube endometrioid adenocarcinoma and endometrioid ovary carcinoma. An important gene associated with Female Reproductive Endometrioid Cancer is POLE (DNA Polymerase Epsilon, Catalytic Subunit), and among its related pathways/superpathways are ERK Signaling and Gene Expression. The drugs Bevacizumab and Atezolizumab have been mentioned in the context of this disorder. Affiliated tissues include ovary, lymph node and breast, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Female Reproductive Endometrioid Cancer

Diseases related to Female Reproductive Endometrioid Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 399)
# Related Disease Score Top Affiliating Genes
1 fallopian tube endometrioid adenocarcinoma 31.8 PMS2 MSH6 ERBB2 ARID1A
2 endometrioid ovary carcinoma 31.3 TP53 PTEN PPP2R1A POLE PIK3CA MSH6
3 adenomyosis 30.0 TP53 PGR ESR1 CTNNB1
4 endometrial hyperplasia 29.0 TP53 PTEN PGR MSH6 MSH2 MLH1
5 endometrial cancer 27.1 TP53 PTEN POLE PMS2 PIK3R1 PIK3CA
6 ovarian endometrial cancer 11.2
7 thyroid hurthle cell adenoma 10.4 PTEN PIK3CA
8 hepatic flexure cancer 10.4 KRAS HRAS
9 trachea carcinoma in situ 10.4 KRAS HRAS
10 signet ring basal cell carcinoma 10.4 KRAS HRAS
11 cobblestone retinal degeneration 10.4 KRAS HRAS
12 breast duct papilloma 10.4 PTEN PGR
13 immature teratoma of ovary 10.4 KRAS HRAS
14 spindle cell intraocular melanoma 10.4 PMS2 MLH1
15 vulvar intraepithelial neoplasia 10.4 TP53 CTNNB1
16 papillary adenoma 10.4 TP53 KRAS HRAS
17 ovarian clear cell adenofibroma 10.4 PTEN PIK3CA KRAS
18 clear cell adenofibroma 10.4 PPP2R1A PIK3CA ARID1A
19 descending colon cancer 10.4 KRAS HRAS
20 pancreatic signet ring cell adenocarcinoma 10.4 TP53 KRAS HRAS
21 clear cell adenocarcinoma 10.4 TP53 PIK3CA ARID1A
22 ampulla of vater benign neoplasm 10.4 KRAS HRAS
23 familiar ovarian carcinoma 10.4 PIK3CA BRCA1
24 bartholin's gland adenoid cystic carcinoma 10.4 PGR ESR1
25 uterine corpus adenosarcoma 10.4 PGR ESR1
26 bone giant cell sarcoma 10.4 TP53 KRAS HRAS
27 anal squamous cell carcinoma 10.4 TP53 PIK3CA MLH1
28 chronic tympanitis 10.4 PGR ESR1
29 lung oat cell carcinoma 10.4 TP53 PTEN PIK3CA
30 liver adenomatosis 10.3 PGR CTNNB1
31 biliary tract benign neoplasm 10.3 TP53 KRAS HRAS
32 malignant exocrine pancreas neoplasm 10.3 TP53 KRAS HRAS
33 ovarian clear cell adenocarcinoma 10.3 TP53 PIK3CA ARID1A
34 colorectal cancer 2 10.3 MSH2 MLH1
35 adenosquamous lung carcinoma 10.3 PIK3CA KRAS HRAS
36 appendix disease 10.3 TP53 KRAS HRAS
37 cystic teratoma 10.3 TP53 PTEN KRAS
38 actinic cheilitis 10.3 TP53 MSH2
39 granulomatous endometritis 10.3 PGR ESR1
40 prostate squamous cell carcinoma 10.3 TP53 PIK3CA HRAS
41 appendix cancer 10.3 TP53 KRAS HRAS
42 spitz nevus 10.3 TP53 HRAS
43 vulvar syringoma 10.3 PGR ESR1
44 nasal cavity adenocarcinoma 10.3 TP53 KRAS HRAS
45 epithelial-myoepithelial carcinoma 10.3 TP53 PIK3CA HRAS
46 myoepithelial carcinoma 10.3 TP53 PIK3CA HRAS
47 oculoectodermal syndrome 10.3 PIK3CA KRAS HRAS
48 eccrine papillary adenoma 10.3 PIK3CA KRAS HRAS
49 silent pituitary adenoma 10.3 MSH6 MSH2
50 lipomatosis 10.3 PTEN PIK3CA KRAS

Graphical network of the top 20 diseases related to Female Reproductive Endometrioid Cancer:



Diseases related to Female Reproductive Endometrioid Cancer

Symptoms & Phenotypes for Female Reproductive Endometrioid Cancer

GenomeRNAi Phenotypes related to Female Reproductive Endometrioid Cancer according to GeneCards Suite gene sharing:

26 (show top 50) (show all 62)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.83 HRAS KRAS PIK3CA
2 Decreased viability GR00055-A-2 10.83 HRAS KRAS PIK3CA
3 Decreased viability GR00055-A-3 10.83 KRAS
4 Decreased viability GR00106-A-0 10.83 KRAS
5 Decreased viability GR00221-A-1 10.83 ESR1 HRAS KRAS PIK3CA PIK3R1
6 Decreased viability GR00221-A-2 10.83 BRCA1 ESR1 HRAS KRAS PIK3CA
7 Decreased viability GR00221-A-3 10.83 BRCA1 HRAS PIK3R1
8 Decreased viability GR00221-A-4 10.83 ESR1 PIK3CA
9 Decreased viability GR00301-A 10.83 BRCA1 KRAS
10 Decreased viability GR00381-A-1 10.83 KRAS
11 Decreased viability GR00386-A-1 10.83 ESR1
12 Decreased viability GR00402-S-2 10.83 ESR1 PIK3CA
13 Increased shRNA abundance (Z-score > 2) GR00366-A-1 10.7 POLE
14 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.7 PIK3R1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.7 MSH2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.7 KRAS
17 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.7 POLE
18 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.7 BRCA1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-139 10.7 BRCA1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-14 10.7 MSH2 PMS2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.7 MSH2 PTEN
22 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.7 PTEN
23 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.7 ERBB2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.7 ARID1A BRCA1 ERBB2 POLE PTEN
25 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.7 ARID1A MSH2
26 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.7 PIK3R1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-186 10.7 ARID1A
28 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.7 PMS2
29 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.7 ARID1A
30 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.7 HRAS
31 Increased shRNA abundance (Z-score > 2) GR00366-A-197 10.7 PMS2
32 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.7 PIK3R1 POLE
33 Increased shRNA abundance (Z-score > 2) GR00366-A-204 10.7 BRCA1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.7 ERBB2 PMS2 POLE
35 Increased shRNA abundance (Z-score > 2) GR00366-A-211 10.7 BRCA1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-213 10.7 ARID1A
37 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.7 MSH2 PIK3R1 PTEN
38 Increased shRNA abundance (Z-score > 2) GR00366-A-22 10.7 KRAS
39 Increased shRNA abundance (Z-score > 2) GR00366-A-28 10.7 HRAS
40 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.7 ERBB2 POLE
41 Increased shRNA abundance (Z-score > 2) GR00366-A-34 10.7 PIK3R1
42 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.7 PTEN
43 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.7 ARID1A PIK3R1
44 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.7 PMS2
45 Increased shRNA abundance (Z-score > 2) GR00366-A-53 10.7 MSH2
46 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.7 ERBB2
47 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.7 ERBB2 KRAS POLE PTEN
48 Increased shRNA abundance (Z-score > 2) GR00366-A-66 10.7 PTEN
49 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.7 ARID1A
50 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.7 HRAS

MGI Mouse Phenotypes related to Female Reproductive Endometrioid Cancer:

46 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.51 ARID1A BRCA1 BRCA2 CTNNB1 ELAPOR1 ERBB2
2 homeostasis/metabolism MP:0005376 10.48 ARID1A BRCA1 BRCA2 CTNNB1 ERBB2 ESR1
3 mortality/aging MP:0010768 10.46 ARID1A BRCA1 BRCA2 CTNNB1 ELAPOR1 ERBB2
4 behavior/neurological MP:0005386 10.44 BRCA1 BRCA2 CTNNB1 ELAPOR1 ERBB2 ESR1
5 hematopoietic system MP:0005397 10.44 ARID1A BRCA1 BRCA2 CTNNB1 ELAPOR1 ESR1
6 immune system MP:0005387 10.44 ARID1A BRCA1 BRCA2 CTNNB1 ELAPOR1 ESR1
7 endocrine/exocrine gland MP:0005379 10.43 ARID1A BRCA1 BRCA2 CTNNB1 ERBB2 ESR1
8 cardiovascular system MP:0005385 10.4 ARID1A BRCA1 CTNNB1 ELAPOR1 ERBB2 ESR1
9 integument MP:0010771 10.4 BRCA1 BRCA2 CTNNB1 ERBB2 ESR1 HRAS
10 neoplasm MP:0002006 10.38 ARID1A BRCA1 BRCA2 CTNNB1 ERBB2 ESR1
11 growth/size/body region MP:0005378 10.36 ARID1A BRCA1 BRCA2 CTNNB1 ERBB2 ESR1
12 digestive/alimentary MP:0005381 10.35 BRCA1 BRCA2 CTNNB1 ERBB2 ESR1 HRAS
13 embryo MP:0005380 10.31 ARID1A BRCA1 BRCA2 CTNNB1 ERBB2 ESR1
14 muscle MP:0005369 10.21 ARID1A BRCA1 CTNNB1 ERBB2 ESR1 HRAS
15 limbs/digits/tail MP:0005371 10.18 BRCA1 BRCA2 CTNNB1 ELAPOR1 ERBB2 ESR1
16 nervous system MP:0003631 10.18 ARID1A BRCA1 BRCA2 CTNNB1 ERBB2 ESR1
17 normal MP:0002873 10.07 ARID1A BRCA1 BRCA2 CTNNB1 ERBB2 ESR1
18 reproductive system MP:0005389 10 ARID1A BRCA1 BRCA2 CTNNB1 ELAPOR1 ERBB2
19 no phenotypic analysis MP:0003012 9.92 ARID1A CTNNB1 ESR1 HRAS KRAS PGR
20 respiratory system MP:0005388 9.61 BRCA1 CTNNB1 ERBB2 ESR1 HRAS KRAS
21 skeleton MP:0005390 9.44 ARID1A BRCA1 BRCA2 CTNNB1 ELAPOR1 ERBB2

Drugs & Therapeutics for Female Reproductive Endometrioid Cancer

Drugs for Female Reproductive Endometrioid Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 24)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 2 216974-75-3
2
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
3
Olaparib Approved Phase 2 763113-22-0 23725625
4
Ipilimumab Approved Phase 2 477202-00-9
5
Acetylcysteine Approved, Investigational Phase 2 616-91-1 12035
6
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60700
7
Cysteine Approved, Nutraceutical Phase 2 52-90-4 5862
8
Tremelimumab Investigational Phase 2 745013-59-6
9 Angiogenesis Inhibitors Phase 2
10 Immunoglobulins, Intravenous Phase 2
11 Antineoplastic Agents, Immunological Phase 2
12 Antibodies Phase 2
13 Immunoglobulins Phase 2
14 Antibodies, Monoclonal Phase 2
15 Poly(ADP-ribose) Polymerase Inhibitors Phase 2
16 topoisomerase I inhibitors Phase 2
17 Respiratory System Agents Phase 2
18 Antidotes Phase 2
19 Expectorants Phase 2
20 N-monoacetylcystine Phase 2
21 Antioxidants Phase 2
22 Antiviral Agents Phase 2
23 Anti-Infective Agents Phase 2
24 Protective Agents Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Life on the Go 2: Evaluating the Effect of Physical Activity of Patients With Recurrent Ovarian Cancer Using State of the Art Activity Tracking Device Completed NCT03685695 Phase 2
2 Halting Early Advancement of Residual Disease by Treatment With Bevacizumab and Atezolizumab in Ovarian Cancer Not yet recruiting NCT04510584 Phase 2 Atezolizumab;Bevacizumab
3 A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer Suspended NCT04034927 Phase 2 Olaparib
4 Evaluation of the Addition of N-Acetylcysteine to Topotecan in the Tumor Microenvironment of Persistent or Recurrent High Grade Endometrioid or Serous Ovarian Carcinoma Terminated NCT02569957 Phase 2 Topotecan Hydrochloride;Topotecan Hydrochloride;Acetylcysteine

Search NIH Clinical Center for Female Reproductive Endometrioid Cancer

Genetic Tests for Female Reproductive Endometrioid Cancer

Anatomical Context for Female Reproductive Endometrioid Cancer

MalaCards organs/tissues related to Female Reproductive Endometrioid Cancer:

40
Ovary, Lymph Node, Breast, Uterus, Prostate

Publications for Female Reproductive Endometrioid Cancer

Articles related to Female Reproductive Endometrioid Cancer:

(show top 50) (show all 51)
# Title Authors PMID Year
1
Primary endometrioid carcinoma of the uterosacral ligament arising from deep infiltrating endometriosis 6 years after bilateral salpingo-oophorectomy due to atypical proliferative endometrioid tumor of the ovary: a rare case report. 61
33308243 2020
2
Characterization of miR-200 family members as blood biomarkers for human and laying hen ovarian cancer. 61
33208870 2020
3
Assessment of Preoperative Endometrial Histopathological Sampling as a Predictor of Final Surgical Pathology in Endometrial Cancer. 61
33129220 2020
4
Validation of ultrasound strategies to assess tumor extension and to predict high-risk endometrial cancer in women from the prospective IETA (International Endometrial Tumor Analysis)-4 cohort. 61
31225683 2020
5
Ovarian Seromucinous Tumors: Pathogenesis, Morphologic Spectrum, and Clinical Issues. 61
32023964 2020
6
Omental Micrometastasis in Endometrial Cancer. 61
31340208 2019
7
Sertoliform Endometrioid Tumor of Ovary Presenting as Torsion. 61
27365921 2016
8
Elevated serum progesterone levels in postmenopausal women with mucinous ovarian tumors. 61
26926326 2016
9
Atypical proliferative endometrioid tumor of ovary: Report of a rare case. 61
26497398 2016
10
Association of specific PTEN/10q haplotypes with endometrial cancer phenotypes in African-American and European American women. 61
26026735 2015
11
Significance of p53 expression in background endometrium in endometrial carcinoma. 61
25788166 2015
12
Contrast-enhanced MRI in preoperative assessment of myometrial and cervical invasion, and lymph node metastasis: diagnostic value and error analysis in endometrial carcinoma. 61
25545203 2015
13
Prediction of staging with preoperative parameters and frozen/section in patients with a preoperative diagnosis of grade 1 endometrioid tumor in endometrial cancer. 61
24790516 2014
14
Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A. 61
22653341 2012
15
Differential expression of secreted phosphoprotein 1 in response to estradiol-17β and in ovarian tumors in chickens. 61
22588173 2012
16
[Ovarian preservation during treatment of early stage endometrial cancer]. 61
22198406 2012
17
Recommendations of the Fertility Task Force of the European Society of Gynecologic Oncology about the conservative management of ovarian malignant tumors. 61
21697684 2011
18
The role of serum CA-125 levels and CA-125 tissue expression positivity in the prediction of the recurrence of stage III and IV epithelial ovarian tumors (CA-125 levels and tissue CA-125 in ovarian tumors). 61
20645105 2011
19
Determination of glycodelin-A expression correlated to grading and staging in ovarian carcinoma tissue. 61
20592354 2010
20
[Clinicopathological features of endometrial carcinoma in tamoxifen- and toremifene-treated breast cancer patients]. 61
20154485 2010
21
Immunohistochemical characterization of mullerian mucinous borderline tumors: possible histogenetic link with serous borderline tumors and low-grade endometrioid tumors. 61
19269675 2009
22
Comparative proteomic study of two closely related ovarian endometrioid adenocarcinoma cell lines using cIEF fractionation and pathway analysis. 61
19288585 2009
23
Adult extrarenal Wilms tumor of the uterus with teratoid features. 61
18789483 2009
24
Combined large cell neuroendocrine and endometrioid carcinoma of the endometrium. 61
18156975 2008
25
Antisense suppression of pygopus2 results in growth arrest of epithelial ovarian cancer. 61
16609037 2006
26
Borderline endometrioid tumor arising in a paratubal cyst: a case report. 61
15790473 2005
27
Risk factors for different histological types of ovarian cancer. 61
15228415 2004
28
Ovarian endometrioid tumors of low malignant potential: a clinicopathologic study of 30 cases with comparison to well-differentiated endometrioid adenocarcinoma. 61
12960810 2003
29
Metastatic endocervical adenocarcinoma presenting as a virilizing ovarian mass during pregnancy. 61
12423833 2002
30
Morules with optically clear nuclei in ovarian borderline endometrioid tumor. 61
12588418 2002
31
The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy. 61
12060448 2002
32
Endometrioid adenocarcinomas of the uterine corpus in women younger than 50 years of age can be divided into two distinct clinical and pathologic entities based on anatomic location. 61
11745192 2001
33
Cellular apoptosis susceptibility gene expression in endometrial carcinoma: correlation with Bcl-2, Bax, and caspase-3 expression and outcome. 61
11603220 2001
34
Androgen-producing, atypically proliferating endometrioid tumor arising in endometriosis. 61
11332919 2001
35
P53, bcl-2, and bax: their relationship and effect on prognosis in early stage epithelial ovarian carcinoma. 61
11328414 2001
36
beta-catenin expression pattern in stage I and II ovarian carcinomas : relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome. 61
10433945 1999
37
[Borderline ovarian tumors: a series of 43 patients]. 61
9497606 1997
38
Reliability of tumor typing of endometrial carcinoma in prehysterectomy curettage. 61
7883421 1995
39
Genome scanning detects genetic alterations in human ovarian carcinoma. 61
7981718 1994
40
Proliferative endometrioid tumors and endometrioid tumors of low malignant potential of the ovary. 61
8463037 1993
41
Epithelial ovarian tumors of borderline malignancy: a study of 50 cases. 61
11576258 1992
42
[An immunohistochemical study of ferritin in ovarian epithelial tumours]. 61
1323423 1992
43
An analysis of abnormalities of the retinoblastoma gene in human ovarian and endometrial carcinoma. 61
2224770 1990
44
Endometrioid carcinoma of the fallopian tube: pathology and clinical outcome. 61
1972104 1990
45
Therapeutic and staging operations for endometrial carcinomas. 61
2639228 1989
46
Endometrioid proliferative and low malignant potential tumors of the ovary. A clinicopathologic study of 46 cases. 61
3414893 1988
47
Adenocarcinoma of the prostate with endometrioid features. A light microscopic and immunohistochemical study of ten cases. 61
2416422 1986
48
Sertoli--Leydig cell tumor with endometroid differentiation. Case report and discussion of histogenesis. 61
7117116 1982
49
Ovarian endometrioid adenofibromatous and cystadenofibromatous tumors: benign, proliferating, and malignant. 61
7284979 1981
50
A case of ovarian endometrioid carcinoma and malignant transformation of adenomyosis uteri. 61
7310201 1981

Variations for Female Reproductive Endometrioid Cancer

Expression for Female Reproductive Endometrioid Cancer

Search GEO for disease gene expression data for Female Reproductive Endometrioid Cancer.

Pathways for Female Reproductive Endometrioid Cancer

Pathways related to Female Reproductive Endometrioid Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 140)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.94 TP53 PTEN PPP2R1A PIK3R1 KRAS HRAS
2
Show member pathways
13.92 TP53 PTEN PPP2R1A PMS2 PGR MSH2
3
Show member pathways
13.82 TP53 PPP2R1A PIK3R1 KRAS HRAS ESR1
4
Show member pathways
13.65 TP53 PPP2R1A PIK3R1 PIK3CA KRAS HRAS
5
Show member pathways
13.57 TP53 PTEN PPP2R1A PIK3R1 PIK3CA KRAS
6
Show member pathways
13.46 TP53 PPP2R1A PIK3R1 PIK3CA KRAS HRAS
7
Show member pathways
13.39 PPP2R1A PIK3R1 KRAS HRAS ESR1 ERBB2
8
Show member pathways
13.33 TP53 POLE PMS2 MSH6 MSH2 MLH1
9
Show member pathways
13.32 TP53 PPP2R1A PIK3R1 PIK3CA KRAS HRAS
10
Show member pathways
13.22 TP53 PTEN PPP2R1A PIK3R1 PIK3CA ERBB2
11
Show member pathways
13.2 TP53 PTEN PIK3R1 PIK3CA KRAS HRAS
12
Show member pathways
13.08 TP53 PTEN PPP2R1A PMS2 MSH2 MLH1
13
Show member pathways
13.08 TP53 PTEN PPP2R1A PIK3R1 PIK3CA KRAS
14
Show member pathways
13.06 TP53 PIK3R1 PIK3CA KRAS HRAS CTNNB1
15
Show member pathways
13.05 PTEN PPP2R1A PIK3R1 KRAS HRAS CTNNB1
16
Show member pathways
13.04 TP53 PIK3R1 MSH6 MSH2 MLH1 KRAS
17
Show member pathways
13.02 PTEN PIK3R1 PIK3CA KRAS HRAS ERBB2
18
Show member pathways
13.02 PTEN PIK3R1 PIK3CA KRAS HRAS ERBB2
19
Show member pathways
12.98 PTEN PIK3R1 PIK3CA KRAS HRAS ERBB2
20
Show member pathways
12.9 PPP2R1A PIK3R1 KRAS HRAS CTNNB1
21
Show member pathways
12.88 PTEN PIK3R1 PIK3CA KRAS HRAS
22
Show member pathways
12.87 PPP2R1A PIK3R1 PIK3CA KRAS HRAS
23
Show member pathways
12.86 TP53 PTEN PPP2R1A PIK3R1 PIK3CA KRAS
24
Show member pathways
12.84 PIK3R1 PIK3CA KRAS HRAS CTNNB1
25
Show member pathways
12.84 TP53 POLE MSH6 MSH2 ESR1 BRCA2
26
Show member pathways
12.82 TP53 PIK3R1 PIK3CA KRAS HRAS
27
Show member pathways
12.82 TP53 PTEN PIK3R1 PIK3CA KRAS HRAS
28
Show member pathways
12.8 PIK3R1 PIK3CA PGR KRAS HRAS ESR1
29
Show member pathways
12.78 TP53 PPP2R1A PIK3R1 KRAS HRAS
30
Show member pathways
12.78 TP53 PTEN PIK3R1 PIK3CA MSH6 MSH2
31
Show member pathways
12.77 TP53 PTEN PIK3R1 PIK3CA KRAS HRAS
32
Show member pathways
12.76 PIK3R1 PIK3CA KRAS HRAS CTNNB1
33
Show member pathways
12.72 PTEN PIK3R1 PIK3CA KRAS HRAS
34
Show member pathways
12.72 TP53 PIK3R1 PIK3CA MSH2 KRAS HRAS
35
Show member pathways
12.71 PTEN PIK3R1 PIK3CA KRAS HRAS
36
Show member pathways
12.71 TP53 PTEN PIK3R1 PIK3CA MSH6 KRAS
37
Show member pathways
12.69 PPP2R1A PIK3R1 PIK3CA KRAS HRAS
38 12.67 TP53 PTEN PIK3R1 PIK3CA KRAS HRAS
39 12.66 TP53 PPP2R1A MSH6 MSH2 MLH1 BRCA2
40
Show member pathways
12.65 TP53 PTEN PIK3R1 PIK3CA KRAS HRAS
41
Show member pathways
12.64 TP53 PTEN PIK3CA KRAS HRAS CTNNB1
42
Show member pathways
12.63 PTEN PIK3R1 PIK3CA KRAS HRAS ESR1
43
Show member pathways
12.61 TP53 PPP2R1A PIK3R1 PIK3CA HRAS
44
Show member pathways
12.59 TP53 PIK3R1 PIK3CA KRAS HRAS ERBB2
45
Show member pathways
12.58 PTEN PIK3R1 PIK3CA KRAS HRAS
46
Show member pathways
12.55 PIK3R1 PIK3CA KRAS HRAS ESR1 CTNNB1
47
Show member pathways
12.54 PTEN PIK3R1 PIK3CA KRAS HRAS
48
Show member pathways
12.53 PIK3R1 PIK3CA KRAS HRAS ERBB2 CTNNB1
49
Show member pathways
12.53 TP53 PTEN PIK3R1 PIK3CA HRAS
50
Show member pathways
12.51 PIK3R1 PIK3CA KRAS HRAS

GO Terms for Female Reproductive Endometrioid Cancer

Cellular components related to Female Reproductive Endometrioid Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.29 PTEN PPP2R1A POLE PMS2 PIK3R1 PIK3CA
2 cytosol GO:0005829 10.1 TP53 PTEN PPP2R1A PMS2 PIK3R1 PIK3CA
3 nucleus GO:0005634 10.09 TP53 PTEN PPP2R1A POLE PMS2 PIK3R1
4 protein-containing complex GO:0032991 9.93 TP53 PIK3R1 ESR1 CTNNB1 BRCA2 BRCA1
5 chromosome GO:0005694 9.88 PPP2R1A MSH6 MSH2 MLH1 BRCA2 BRCA1
6 nucleoplasm GO:0005654 9.8 TP53 PTEN POLE PMS2 PGR MSH6
7 MutLalpha complex GO:0032389 9.43 PMS2 MLH1
8 MutSalpha complex GO:0032301 9.37 MSH6 MSH2
9 phosphatidylinositol 3-kinase complex, class IA GO:0005943 9.32 PIK3R1 PIK3CA
10 mismatch repair complex GO:0032300 8.92 PMS2 MSH6 MSH2 MLH1

Biological processes related to Female Reproductive Endometrioid Cancer according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.19 TP53 PIK3R1 PGR HRAS ESR1 CTNNB1
2 positive regulation of transcription, DNA-templated GO:0045893 10.11 TP53 ESR1 CTNNB1 BRCA2 BRCA1 ARID1A
3 negative regulation of gene expression GO:0010629 9.98 TP53 PGR HRAS ESR1 CTNNB1
4 positive regulation of gene expression GO:0010628 9.98 TP53 PTEN KRAS HRAS ERBB2 CTNNB1
5 heart development GO:0007507 9.97 TP53 PTEN ERBB2 CTNNB1
6 positive regulation of protein kinase B signaling GO:0051897 9.93 PIK3R1 PIK3CA ESR1 ERBB2
7 DNA repair GO:0006281 9.91 POLE PMS2 MSH6 MSH2 MLH1 BRCA2
8 negative regulation of neuron apoptotic process GO:0043524 9.89 PIK3CA MSH2 KRAS HRAS
9 phosphatidylinositol biosynthetic process GO:0006661 9.84 PTEN PIK3R1 PIK3CA
10 Ras protein signal transduction GO:0007265 9.83 TP53 KRAS HRAS
11 positive regulation of MAP kinase activity GO:0043406 9.82 KRAS HRAS ERBB2
12 embryonic organ development GO:0048568 9.77 TP53 POLE CTNNB1
13 double-strand break repair GO:0006302 9.76 TP53 MSH2 BRCA2 BRCA1
14 cellular response to DNA damage stimulus GO:0006974 9.76 TP53 POLE PMS2 MSH6 MSH2 MLH1
15 intrinsic apoptotic signaling pathway GO:0097193 9.75 TP53 MSH6 HRAS
16 ERBB2 signaling pathway GO:0038128 9.74 PIK3R1 PIK3CA ERBB2
17 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.73 TP53 MSH2 BRCA2
18 cell aging GO:0007569 9.72 TP53 HRAS BRCA2
19 phosphatidylinositol 3-kinase signaling GO:0014065 9.71 PTEN PIK3R1 PIK3CA ERBB2
20 response to X-ray GO:0010165 9.7 TP53 MSH2 BRCA2
21 determination of adult lifespan GO:0008340 9.69 TP53 MSH6 MSH2
22 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.68 TP53 ESR1
23 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.67 TP53 ESR1
24 intracellular steroid hormone receptor signaling pathway GO:0030518 9.67 PGR ESR1
25 isotype switching GO:0045190 9.67 MSH6 MSH2 MLH1
26 positive regulation of isotype switching to IgG isotypes GO:0048304 9.65 MSH2 MLH1
27 response to isolation stress GO:0035900 9.65 KRAS HRAS
28 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.65 TP53 BRCA2 BRCA1
29 positive regulation of helicase activity GO:0051096 9.63 MSH6 MSH2
30 cellular response to indole-3-methanol GO:0071681 9.62 CTNNB1 BRCA1
31 positive regulation of isotype switching to IgA isotypes GO:0048298 9.62 MSH2 MLH1
32 mismatch repair GO:0006298 9.62 PMS2 MSH6 MSH2 MLH1
33 maintenance of DNA repeat elements GO:0043570 9.61 MSH6 MSH2
34 chordate embryonic development GO:0043009 9.61 BRCA2 BRCA1
35 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.54 MSH2 MLH1
36 somatic recombination of immunoglobulin gene segments GO:0016447 9.43 MSH6 MSH2 MLH1
37 somatic hypermutation of immunoglobulin genes GO:0016446 9.26 PMS2 MSH6 MSH2 MLH1
38 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.1 PIK3R1 MSH6 MSH2 MLH1 BRCA2 BRCA1

Molecular functions related to Female Reproductive Endometrioid Cancer according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.48 TP53 PTEN PPP2R1A POLE PMS2 PIK3R1
2 nucleotide binding GO:0000166 10.19 POLE PIK3CA MSH6 MSH2 MLH1 KRAS
3 identical protein binding GO:0042802 10.16 TP53 PTEN PGR KRAS ESR1 ERBB2
4 DNA binding GO:0003677 10.16 TP53 POLE PMS2 PGR MSH6 MSH2
5 protein kinase binding GO:0019901 9.97 TP53 PTEN MSH2 ESR1 CTNNB1
6 chromatin binding GO:0003682 9.8 TP53 POLE MSH6 MSH2 MLH1 ESR1
7 damaged DNA binding GO:0003684 9.74 MSH6 MSH2 BRCA1
8 single-stranded DNA binding GO:0003697 9.73 PMS2 MSH2 MLH1 BRCA2
9 protein C-terminus binding GO:0008022 9.72 MSH2 HRAS ERBB2 CTNNB1 BRCA2
10 protein phosphatase binding GO:0019903 9.67 TP53 PIK3R1 ERBB2 CTNNB1
11 insulin receptor substrate binding GO:0043560 9.59 PIK3R1 PIK3CA
12 MutSalpha complex binding GO:0032407 9.55 PMS2 MLH1
13 MutLalpha complex binding GO:0032405 9.54 MSH6 MSH2
14 oxidized purine DNA binding GO:0032357 9.52 MSH6 MSH2
15 ErbB-3 class receptor binding GO:0043125 9.51 PIK3R1 ERBB2
16 single guanine insertion binding GO:0032142 9.49 MSH6 MSH2
17 single thymine insertion binding GO:0032143 9.4 MSH6 MSH2
18 guanine/thymine mispair binding GO:0032137 9.33 MSH6 MSH2 MLH1
19 enzyme binding GO:0019899 9.28 TP53 PTEN PGR MSH6 MSH2 MLH1
20 mismatched DNA binding GO:0030983 9.26 PMS2 MSH6 MSH2 MLH1

Sources for Female Reproductive Endometrioid Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....